Oculis Announces FDA Pre-IND Feedback Regarding Privosegtors Clinical Development Plan

(RTTNews) - Oculis Holding AG (OCS) announced positive FDA pre-IND feedback regarding Privosegtors clinical development plan in acute multiple sclerosis relapses. The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis relapses. The FDA confirmed that existing Privosegtor data can be cross-referenced for a new Investigational New Drug application in acute MS relapses, planned for submission in the fourth quarter of 2026.

Oculis plans to host an R&D Day in the fourth quarter of 2026 to review additional details on the pivotal development program for Privosegtor in acute MS relapses and provide a comprehensive update on the PIONEER program in optic neuropathies.

In pre-market trading on NasdaqGM, Oculis shares are up 4.97 percent to $11.87.

For More Such Health News, visit rttnews.com.